Literature DB >> 24118860

Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.

H Florez1, M G Temprosa, T J Orchard, K J Mather, S M Marcovina, E Barrett-Connor, E Horton, C Saudek, X F Pi-Sunyer, R E Ratner, R B Goldberg.   

Abstract

AIMS: To determine the association of metabolic syndrome (MetS) and its components with diabetes risk in participants with impaired glucose tolerance (IGT), and whether intervention-related changes in MetS lead to differences in diabetes incidence.
METHODS: We used the National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) revised MetS definition at baseline and intervention-related changes of its components to predict incident diabetes using Cox models in 3234 Diabetes Prevention Program (DPP) participants with IGT over an average follow-up of 3.2 years.
RESULTS: In an intention-to-treat analysis, the demographic-adjusted hazard ratios (95% confidence interval) for diabetes in those with MetS (vs. no MetS) at baseline were 1.7 (1.3-2.3), 1.7 (1.2-2.3) and 2.0 (1.3-3.0) for placebo, metformin and lifestyle groups, respectively. Higher levels of fasting plasma glucose and triglycerides at baseline were independently associated with increased risk of diabetes. Greater waist circumference (WC) was associated with higher risk in placebo and lifestyle groups, but not in the metformin group. In a multivariate model, favourable changes in WC (placebo and lifestyle) and high-density lipoprotein cholesterol (placebo and metformin) contributed to reduced diabetes risk.
CONCLUSIONS: MetS and some of its components are associated with increased diabetes incidence in persons with IGT in a manner that differed according to DPP intervention. After hyperglycaemia, the most predictive factors for diabetes were baseline hypertriglyceridaemia and both baseline and lifestyle-associated changes in WC. Targeting these cardiometabolic risk factors may help to assess the benefits of interventions that reduce diabetes incidence. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  cardiometabolic risk; diabetes prevention; lifestyle; metformin

Mesh:

Substances:

Year:  2013        PMID: 24118860      PMCID: PMC3943638          DOI: 10.1111/dom.12220

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  29 in total

Review 1.  Muscle triglyceride and insulin resistance.

Authors:  David E Kelley; Bret H Goodpaster; Len Storlien
Journal:  Annu Rev Nutr       Date:  2002-01-04       Impact factor: 11.848

Review 2.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

3.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.

Authors: 
Journal:  Diabetes Care       Date:  1997-07       Impact factor: 19.112

4.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

Authors:  T W Gress; F J Nieto; E Shahar; M R Wofford; F L Brancati
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

Review 5.  Diabetes mellitus. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1985

6.  The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  1999-04       Impact factor: 19.112

7.  Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion.

Authors:  D I Phillips; P M Clark; C N Hales; C Osmond
Journal:  Diabet Med       Date:  1994-04       Impact factor: 4.359

8.  The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study.

Authors:  Carlos Lorenzo; Mayor Okoloise; Ken Williams; Michael P Stern; Steven M Haffner
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

9.  Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study.

Authors:  Ronald M A Henry; Piet J Kostense; Annemieke M W Spijkerman; Jacqueline M Dekker; Giel Nijpels; Robert J Heine; Otto Kamp; Nico Westerhof; Lex M Bouter; Coen D A Stehouwer
Journal:  Circulation       Date:  2003-04-14       Impact factor: 29.690

Review 10.  Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta-analysis.

Authors:  A J Dunkley; K Charles; L J Gray; J Camosso-Stefinovic; M J Davies; K Khunti
Journal:  Diabetes Obes Metab       Date:  2012-02-21       Impact factor: 6.577

View more
  14 in total

1.  Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy?

Authors:  Shannon D Sullivan; Robert E Ratner
Journal:  Curr Diab Rep       Date:  2011-04       Impact factor: 4.810

Review 2.  Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; Gabriel Gimenez-Perez; Didac Mauricio; Marta Roqué I Figuls; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2017-12-04

3.  Improving employee health: evaluation of a worksite lifestyle change program to decrease risk factors for diabetes and cardiovascular disease.

Authors:  M Kaye Kramer; Donald M Molenaar; Vincent C Arena; Elizabeth M Venditti; Rebecca J Meehan; Rachel G Miller; Karl K Vanderwood; Yvonne Eaglehouse; Andrea M Kriska
Journal:  J Occup Environ Med       Date:  2015-03       Impact factor: 2.162

4.  Prevention of Diabetes Through the Lifestyle Intervention: Lessons Learned from the Diabetes Prevention Program and Outcomes Study and its Translation to Practice.

Authors:  Mary A Hoskin; George A Bray; Kathy Hattaway; Prajakta A Khare-Ranade; Jeremy Pomeroy; Linda N Semler; Valarie A Weinzierl; Judith Wylie-Rosett
Journal:  Curr Nutr Rep       Date:  2014-12-01

Review 5.  Prediabetes and associated disorders.

Authors:  Martin Buysschaert; José Luís Medina; Michael Bergman; Avni Shah; Jaqueline Lonier
Journal:  Endocrine       Date:  2014-10-08       Impact factor: 3.633

6.  Tang-Nai-Kang alleviates pre-diabetes and metabolic disorders and induces a gene expression switch toward fatty acid oxidation in SHR.Cg-Leprcp/NDmcr rats.

Authors:  Linyi Li; Hisae Yoshitomi; Ying Wei; Lingling Qin; Jingxin Zhou; Tunhai Xu; Xinli Wu; Tian Zhou; Wen Sun; Xiangyu Guo; Lili Wu; Haiyan Wang; Yan Zhang; Chunna Li; Tonghua Liu; Ming Gao
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

7.  Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

Authors:  Kasper S Madsen; Yuan Chi; Maria-Inti Metzendorf; Bernd Richter; Bianca Hemmingsen
Journal:  Cochrane Database Syst Rev       Date:  2019-12-03

Review 8.  The use of expensive technologies instead of simple, sound and effective lifestyle interventions: a perpetual delusion.

Authors:  Silvia Carlos; Jokin de Irala; Matt Hanley; Miguel Ángel Martínez-González
Journal:  J Epidemiol Community Health       Date:  2014-06-24       Impact factor: 3.710

9.  Association of Waist Circumference Gain and Incident Prediabetes Defined by Fasting Glucose: A Seven-Year Longitudinal Study in Beijing, China.

Authors:  Li-Xin Tao; Kun Yang; Fang-Fang Huang; Xiang-Tong Liu; Xia Li; Yan-Xia Luo; Li-Juan Wu; Xiu-Hua Guo
Journal:  Int J Environ Res Public Health       Date:  2017-10-10       Impact factor: 3.390

10.  Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Jinlida Granules on Metabolic Syndrome in Patients With Abnormal Glucose Metabolism.

Authors:  Lili Hou; Shuolong Han; Liping Chang; Huailin Gao; Yiru Zhao; Shenghui Zhao; Xuedong An; Guangyao Song; Chunli Piao; Fengmei Lian; Tong Xiao-Lin; Zhenhua Jia
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-25       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.